BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Salvadori M, Rosso G, Bertoni E. Complement involvement in kidney diseases: From physiopathology to therapeutical targeting. World J Nephrol 2015; 4(2): 169-184 [PMID: 25949931 DOI: 10.5527/wjn.v4.i2.169] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Semis M, Gugiu GB, Bernstein EA, Bernstein KE, Kalkum M. The Plethora of Angiotensin-Converting Enzyme-Processed Peptides in Mouse Plasma. Anal Chem 2019;91:6440-53. [PMID: 31021607 DOI: 10.1021/acs.analchem.8b03828] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
2 Salvadori M, Rosso G. Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN. World J Nephrol 2016; 5(4): 308-320 [PMID: 27458560 DOI: 10.5527/wjn.v5.i4.308] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
3 Mastrangelo A, Serafinelli J, Giani M, Montini G. Clinical and Pathophysiological Insights Into Immunological Mediated Glomerular Diseases in Childhood. Front Pediatr 2020;8:205. [PMID: 32478016 DOI: 10.3389/fped.2020.00205] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Weiss S, Rosendahl A, Czesla D, Meyer-Schwesinger C, Stahl RA, Ehmke H, Kurts C, Zipfel PF, Köhl J, Wenzel UO. The complement receptor C5aR1 contributes to renal damage but protects the heart in angiotensin II-induced hypertension. Am J Physiol Renal Physiol 2016;310:F1356-65. [PMID: 27053686 DOI: 10.1152/ajprenal.00040.2016] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
5 Yiu WH, Li RX, Wong DWL, Wu HJ, Chan KW, Chan LYY, Leung JCK, Lai KN, Sacks SH, Zhou W, Tang SCW. Complement C5a inhibition moderates lipid metabolism and reduces tubulointerstitial fibrosis in diabetic nephropathy. Nephrol Dial Transplant 2018;33:1323-32. [PMID: 29294056 DOI: 10.1093/ndt/gfx336] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
6 Bruschi M, Granata S, Candiano G, Fabris A, Petretto A, Ghiggeri GM, Gambaro G, Zaza G. Proteomic Analysis of Urinary Extracellular Vesicles Reveals a Role for the Complement System in Medullary Sponge Kidney Disease. Int J Mol Sci 2019;20:E5517. [PMID: 31694344 DOI: 10.3390/ijms20215517] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
7 Wymann S, Dai Y, Nair AG, Cao H, Powers GA, Schnell A, Martin-Roussety G, Leong D, Simmonds J, Lieu KG, de Souza MJ, Mischnik M, Taylor S, Ow SY, Spycher M, Butcher RE, Pearse M, Zuercher AW, Baz Morelli A, Panousis C, Wilson MJ, Rowe T, Hardy MP. A novel soluble complement receptor 1 fragment with enhanced therapeutic potential. J Biol Chem 2021;296:100200. [PMID: 33334893 DOI: 10.1074/jbc.RA120.016127] [Reference Citation Analysis]
8 Eldewi DM, Alhabibi AM, El Sayed HME, Mahmoud SAK, El Sadek SM, Gouda RM, Hassan MAEM, Ibrahim AH, Abd El Haliem NF. Expression levels of complement regulatory proteins (CD35, CD55 and CD59) on peripheral blood cells of patients with chronic kidney disease. Int J Gen Med 2019;12:343-51. [PMID: 31571973 DOI: 10.2147/IJGM.S216989] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Rope R, Kambham N, Arora N. A case report of paraproteinemia-associated pauci-immune glomerulonephritis - a new form of monoclonal gammopathy of renal significance? Clin Nephrol Case Stud 2017;5:48-53. [PMID: 29043147 DOI: 10.5414/CNCS109160] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Winnicki W, Pichler P, Mechtler K, Imre R, Steinmacher I, Sengölge G, Knafl D, Beilhack G, Wagner L. A novel approach to immunoapheresis of C3a/C3 and proteomic identification of associates. PeerJ 2019;7:e8218. [PMID: 31871840 DOI: 10.7717/peerj.8218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, Weimer R, Wiesener M, Hohenstein B, Tönshoff B, Büscher R, Fehrenbach H, Gök ÖN, Kirschfink M. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol 2017;187:304-15. [PMID: 27784126 DOI: 10.1111/cei.12890] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
12 Ort M, Dingemanse J, van den Anker J, Kaufmann P. Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. Front Immunol 2020;11:599417. [PMID: 33362783 DOI: 10.3389/fimmu.2020.599417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Oni L. Paediatric immune-mediated renal disease: an overview. Nephrol Dial Transplant 2021;36:596-8. [PMID: 31586428 DOI: 10.1093/ndt/gfz184] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]